Epidemiology of Carbapenem Resistance Determinants Identified in Meropenem-Nonsusceptible <i>Enterobacterales</i> Collected as Part of a Global Surveillance Program, 2012 to 2017
Krystyna M. Kazmierczak, James A. Karlowsky, Boudewijn L. M. de Jonge, Gregory G. Stone, Daniel F. Sahm
Abstract
increased from 2.7% in 2012 to 2014 to 3.8% in 2015 to 2017. This increase could be attributed to the increasing proportion of carbapenemase-positive isolates that was observed, most notably among isolates carrying NDM-type MBLs in Asia/South Pacific, Europe, and Latin America; OXA-48-like carbapenemases in Europe, Middle East/Africa, and Asia/South Pacific; VIM-type MBLs in Europe; and KPC-type carbapenemases in Latin America. Ongoing CRE surveillance combined with a global antimicrobial stewardship strategy, sensitive clinical laboratory detection methods, and adherence to infection control practices will be needed to interrupt the spread of CRE.